Chronic pain, stress and sleep issues affect the health and well-being of millions of people – proper solutions to these problems reflect multi-billion dollar markets.
SynBiotic is a biotech platform striving to challenge the status quo and bring innovation to the solution of these global problems. With our buy & build strategy, we cover the whole value chain and transform the healing power of cannabinoids & terpenes into better solutions for complex problems.
People are looking for solutions to their real-life problems. With cannabinoids we are able to address a multi-billion EU-market for sleep, pain and anxiety solutions with cumulative sales of over € 250 billion for OTC and pharmaceuticals in 2020.
over
people with sleep-related problems, such as disturbed sleep
over
people with chronic pain and similar issues
over
people with anxiety
SynBiotic’s organizational structure is built to cover all value drivers – from research over production to distribution
Beyond Cannabis for a multi-billion market. Regulations, market, and customer readiness make CBD the most promising cannabinoid to start with, building a solid foundation for our platform. But we focus not solely on CBD and THC, but also on other cannabinoids, endocannabinoids and terpenes with high potential.
Most CBX* have not been discovered yet, but studies show that other cannabinoids, beyond THC and CBD, have huge medical potential. In addition, the so called entourage effectis a term used to describe the synergistic effects of combining various chemical compounds found in cannabis. Most commonly, it refers to the interaction between THC/CBD and other cannabinoids or terpenes.
* CBX = all cannabinoids except THC
While CBD from hemp & cannabis plants is still a legal grey area, we focus in parallel on other plants that are rich in cannabinoids, endocannabinoids & terpenes.
SynBiotic SE übernimmt 50,1 % der Unternehmensgruppe von Daniel Kruse zu einer Bewertung von 11.2 Mio. Euro Hanf Farm GmbH, Hempro International GmbH, Hemp Factory
SynBiotic SE: Most important cannabis merger in Europe SynBiotic SE acquires 50.1% of Daniel Kruse’s group of companies at a valuation of EUR 11.2 million
Munich, October 27, 2021. The cannabis company SynBiotic SE has successfully completed another capital increase. 334,000 new shares were placed with institutional investors at an
SynBiotic SE – MAKING CANNABINOIDS ACCESSIBLE.
© 2021 Synbiotic SE | All rights reserved
Imprint Privacy policy
